No Data
No Data
Owning 39% Shares,hedge Funds Owners Seem Interested in Immunic, Inc. (NASDAQ:IMUX),
Immunic Coverage Assumed by Leerink Partners at Outperform
Leerink Partners Initiates Immunic(IMUX.US) With Buy Rating, Announces Target Price $5
Piper Sandler Sticks to Their Buy Rating for Immunic (IMUX)
Express News | Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients With Post Covid Syndrome
Immunic Reports First Patient Enrolled in Investigator-sponsored Post-COVID Syndrome Trial | NASDAQ:IMUX
No Data
No Data